Table 1.
Baseline Characteristics of Study Patients Discharged on Clopidogrel According to ABCD‐GENE Score Groups
| Variable |
High (≥10) ABCD‐GENE score (n=613) |
Low (<10) ABCD‐GENE score (n=3270) |
P value |
|---|---|---|---|
| Age at PCI, y (SD) | 65.9 (12.4) | 61.9 (10.5) | <0.0001 |
| Sex | |||
| Men | 410 (66.9%) | 2506 (76.6%) | <0.0001 |
| Women | 203 (33.1%) | 764 (23.4%) | |
| Body mass index, n (SD) | 31.2 (6.7) | 28.8 (6.1) | <0.0001 |
| Race or ethnicity | |||
| White | 369 (60.2%) | 2173 (66.5%) | 0.0002 |
| East Asian | 167 (27.2%) | 644 (19.7%) | |
| South Asian | 30 (4.9%) | 126 (3.9%) | |
| Black | 17 (2.8%) | 77 (2.4%) | |
| Hispanic or Latino | 14 (2.3%) | 115 (3.5%) | |
| Other/Unknown | 16 (2.6%) | 135 (4.1%) | |
| Cardiovascular risk factors | |||
| Diabetes | 285 (46.5%) | 776 (23.7%) | <0.0001 |
| Hypertension | 442 (72.1%) | 2035 (62.2%) | <0.0001 |
| Dyslipidemia | 341 (55.6%) | 1715 (52.4%) | 0.15 |
| Smoking status | |||
| Current smoker | 107 (18.0%) | 833 (25.9%) | 0.0002 |
| Former/recent | 217 (36.5%) | 1056 (32.8%) | |
| Never smoked | 271 (45.5%) | 1326 (41.2%) | |
| Prior history | |||
| Heart failure | 86 (14.0%) | 240 (7.3%) | <0.0001 |
| Myocardial infarction | 100 (16.3%) | 478 (14.6%) | 0.28 |
| PAD | 22 (3.6%) | 88 (2.7%) | 0.22 |
| PCI | 170 (27.7%) | 757 (23.1%) | 0.01 |
| CABG | 61 (10.0%) | 237 (7.2%) | 0.02 |
| Stroke or TIA | 22 (3.6%) | 88 (2.7%) | 0.22 |
| COPD | 30 (4.9%) | 126 (3.9%) | 0.23 |
| Creatinine clearance <60 mL/min | 200 (32.6%) | 222 (6.8%) | <0.001 |
| Multivessel disease | 265 (43.2%) | 1361 (41.6%) | 0.46 |
| Hospital presentation | |||
| Stable CAD | 123 (20.1%) | 585 (17.9%) | 0.05 |
| Unstable Angina/NSTEMI | 380 (62.0%) | 1990 (60.9%) | |
| STEMI | 110 (17.9%) | 695 (21.3%) | |
| CYP2C19 status (no. of *2 alleles) | |||
| 0 | 166 (27.4%) | 2804 (87.1%) | <0.0001 |
| 1 | 356 (58.7%) | 416 (12.9%) | |
| 2 | 84 (13.9%) | 0 (0.0%) | |
Data are shown as n (%) if not otherwise indicated.
ABCD‐GENE indicates Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping; CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CYP, cytochrome P450; NSTEMI, non–ST‐segment–elevation myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; STEMI, ST‐segment–elevation myocardial infarction; and TIA, transient ischemic attack.